Grant

A Phase 3, Prospective, Randomized, Open-label, Adaptive Group Sequential, Multicenter Trial with Blinded Endpoint Assessment to Evaluate the Efficacy and Safety of TAK-330 for the Reversal of Direct

Sponsored by IQVIA RDS Inc.

Active

$143.9K Funding

1 People

External

Related Topics

clinical trials, pharmacology, drug safety, adaptive design, endpoint assessment

People

Robin Carlson
(CD)
Surgery﹒Clinical Research Manager II